IL248979B - Syntac polypeptides and their uses - Google Patents

Syntac polypeptides and their uses

Info

Publication number
IL248979B
IL248979B IL248979A IL24897916A IL248979B IL 248979 B IL248979 B IL 248979B IL 248979 A IL248979 A IL 248979A IL 24897916 A IL24897916 A IL 24897916A IL 248979 B IL248979 B IL 248979B
Authority
IL
Israel
Prior art keywords
syntac polypeptides
syntac
polypeptides
Prior art date
Application number
IL248979A
Other languages
English (en)
Hebrew (he)
Other versions
IL248979A0 (en
Original Assignee
Albert Einstein College Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Medicine Inc filed Critical Albert Einstein College Medicine Inc
Publication of IL248979A0 publication Critical patent/IL248979A0/en
Publication of IL248979B publication Critical patent/IL248979B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL248979A 2014-06-18 2016-11-15 Syntac polypeptides and their uses IL248979B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462013715P 2014-06-18 2014-06-18
PCT/US2015/035777 WO2015195531A2 (en) 2014-06-18 2015-06-15 Syntac polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
IL248979A0 IL248979A0 (en) 2017-01-31
IL248979B true IL248979B (en) 2020-06-30

Family

ID=54936224

Family Applications (3)

Application Number Title Priority Date Filing Date
IL248979A IL248979B (en) 2014-06-18 2016-11-15 Syntac polypeptides and their uses
IL266570A IL266570B (en) 2014-06-18 2019-05-12 Syntac polypeptides and their uses
IL275307A IL275307B (en) 2014-06-18 2020-06-11 Syntac polypeptides and their uses

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL266570A IL266570B (en) 2014-06-18 2019-05-12 Syntac polypeptides and their uses
IL275307A IL275307B (en) 2014-06-18 2020-06-11 Syntac polypeptides and their uses

Country Status (15)

Country Link
US (5) US20170058015A1 (cg-RX-API-DMAC7.html)
EP (3) EP3157552B1 (cg-RX-API-DMAC7.html)
JP (4) JP6652932B2 (cg-RX-API-DMAC7.html)
KR (1) KR102252119B1 (cg-RX-API-DMAC7.html)
CN (3) CN106456733B (cg-RX-API-DMAC7.html)
AU (3) AU2015277460B2 (cg-RX-API-DMAC7.html)
DK (2) DK3480213T3 (cg-RX-API-DMAC7.html)
ES (2) ES2767259T3 (cg-RX-API-DMAC7.html)
HU (2) HUE047255T2 (cg-RX-API-DMAC7.html)
IL (3) IL248979B (cg-RX-API-DMAC7.html)
PL (2) PL3157552T3 (cg-RX-API-DMAC7.html)
PT (2) PT3157552T (cg-RX-API-DMAC7.html)
SG (2) SG10202006338UA (cg-RX-API-DMAC7.html)
TW (3) TWI696633B (cg-RX-API-DMAC7.html)
WO (1) WO2015195531A2 (cg-RX-API-DMAC7.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500255A (ja) 2012-12-11 2016-01-12 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ ハイスループットなレセプター：リガンド同定の方法
JP2019516665A (ja) * 2016-03-02 2019-06-20 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
US20190046648A1 (en) * 2016-03-03 2019-02-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20190044029A (ko) * 2016-05-18 2019-04-29 알버트 아인슈타인 컬리지 오브 메디슨, 인크. 변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법
WO2018027252A1 (en) * 2016-08-11 2018-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds
DK3558339T5 (da) 2016-12-22 2024-09-02 Cue Biopharma Inc T-celle-modulerende multimere polypeptider og fremgangsmåder til anvendelse deraf
EP3565829A4 (en) * 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
US20200010528A1 (en) * 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
US11407806B2 (en) * 2017-04-06 2022-08-09 Albert Einstein College Of Medicine Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells
EP3638258A4 (en) * 2017-06-12 2021-09-08 Sinai Health System ALLOGRAFT TOLERANCE WITHOUT REQUIRING SYSTEMIC IMMUNE SUPPRESSION
CN107266581B (zh) * 2017-06-13 2021-07-09 四川大学 藏猪il-12重组质粒增强pcv2疫苗免疫佐剂的制备方法及应用
WO2019030581A1 (en) * 2017-08-10 2019-02-14 Grifols Diagnostic Solutions Inc. COMPOSITIONS, METHODS AND / OR KITS COMPRISING AN EXTRACELLULAR DOMAIN OF RECOMBINANT HUMAN CD38
KR20200064083A (ko) * 2017-09-07 2020-06-05 큐 바이오파마, 인크. 항원-제시 폴리펩티드 및 이의 사용 방법
IL272085B2 (en) * 2017-09-07 2023-03-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of use thereof
CN111315768A (zh) * 2017-09-07 2020-06-19 库尔生物制药有限公司 具有缀合位点的t细胞调节性多聚体多肽及其使用方法
TW201925235A (zh) * 2017-09-07 2019-07-01 美商信號生物製藥公司 具有化學結合位點之抗原呈現多肽及其使用方法
CN110167959A (zh) * 2017-11-30 2019-08-23 盖立复诊断解决方案公司 用于监测对免疫检查点抑制剂pd1和pd-l1的抗体治疗的免疫测定和工程化蛋白
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
HUE070158T2 (hu) 2018-03-24 2025-05-28 Regeneron Pharma Genetikailag módosított egerek vagy patkányok peptid-mhc komplexek elleni terápiás antitestek létrehozásra, ezek elõállítására szolgáló módszerek, valamint alkalmazásuk
US20220047710A1 (en) * 2018-09-12 2022-02-17 Washington University Single chain constructs
US20220016181A1 (en) * 2018-12-13 2022-01-20 Sinai Health System Immunomodulatory cells and uses thereof
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
AU2019401183A1 (en) * 2018-12-19 2021-08-12 Cue Biopharma, Inc. Multimeric T-cell modulatory polypeptides and methods of use thereof
EP3897690A4 (en) * 2018-12-19 2022-09-28 Cue Biopharma, Inc. T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
EP3935080A4 (en) * 2019-03-06 2023-04-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2020180501A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. T-cell modulatory antigen-presenting polypeptides and methods of use thereof
EP3976084A4 (en) * 2019-05-29 2023-06-21 Cue Biopharma, Inc. MULTIMERIC T LYMPHOCYTE MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
EP3986448A4 (en) * 2019-06-19 2023-07-12 Cue Biopharma, Inc. MULTIMERIC T-CELL-MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
CA3146591A1 (en) * 2019-09-20 2021-03-25 Ronald D. Seidel Iii T-cell modulatory polypeptides and methods of use thereof
JP2023500574A (ja) * 2019-10-23 2023-01-10 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節性キメラ分子及びその使用方法
WO2021127495A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
US20230076204A1 (en) * 2020-02-18 2023-03-09 Institute For Systems Biology Single chain trimer mhc class ii nucleic acids and proteins and methods of use
EP4106790A4 (en) * 2020-02-21 2024-02-21 3T Biosciences, Inc. YEAST DISPLAY LIBRARIES, RELATED COMPOSITIONS AND RELATED METHODS OF USE
US20230126784A1 (en) * 2020-03-06 2023-04-27 Albert Einstein College Of Medicine A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
CA3178427A1 (en) * 2020-05-12 2021-11-18 Lg Chem, Ltd. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022056015A1 (en) * 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereof
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
CN112779224A (zh) * 2021-01-27 2021-05-11 河南省华隆生物技术有限公司 一种表达细胞因子组合物的nk滋养层细胞及其制备方法和应用
CN112725284A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk滋养层细胞及其应用
CN112725273A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk细胞及其制备方法和应用
CN112852744A (zh) * 2021-01-27 2021-05-28 河南省华隆生物技术有限公司 一种nk滋养层细胞及其制备方法和应用
CA3209361A1 (en) * 2021-03-19 2022-09-22 Ronald D. Seidel Iii T-cell modulatory polypeptides and methods of use thereof
WO2022216974A1 (en) * 2021-04-07 2022-10-13 Repertoire Immune Medicines, Inc. Peptide-mhc-immunoglobulin multimers and methods of use thereof
CN117730151A (zh) * 2021-05-07 2024-03-19 系统生物学研究所 单链三聚体mhcⅰ类核酸和蛋白质以及使用方法
AU2022331241A1 (en) 2021-08-16 2024-03-28 Regeneron Pharmaceuticals, Inc. Novel il27 receptor agonists and methods of use thereof
US20240376464A1 (en) * 2021-08-20 2024-11-14 3T Biosciences, Inc. PEPTIDE-HLA-B*35 Libraries, Associated Compositions, and Associated Methods of Use
US20250059254A1 (en) * 2022-01-03 2025-02-20 Aarhus Universitet Proteinaceous compound for generating specific cytotoxic t-cell effect
US20250271443A1 (en) * 2022-04-21 2025-08-28 Institute For Systems Biology Soluble single-chain dimers from cleavable single chain trimers
KR20250035053A (ko) 2022-06-07 2025-03-11 리제너론 파아마슈티컬스, 인크. T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2024059740A1 (en) * 2022-09-14 2024-03-21 Synthego Corporation Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof
WO2024159071A1 (en) 2023-01-27 2024-08-02 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
US20240287186A1 (en) 2023-02-28 2024-08-29 Regeneron Pharmaceuticals, Inc. T cell activators and methods of use thereof
WO2025081106A2 (en) * 2023-10-12 2025-04-17 Vanderbilt University Nanobody vaccine compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
DE69434486T2 (de) 1993-06-24 2006-07-06 Advec Inc. Adenovirus vektoren für gentherapie
BR9407956A (pt) 1993-10-25 1996-11-26 Canji Inc Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6211342B1 (en) * 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
WO2002072631A2 (en) * 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Mhc molecule constructs and their usesfor diagnosis and therapy
DE102004014983A1 (de) * 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
AU2007223888A1 (en) 2006-03-06 2007-09-13 Amunix, Inc. Genetic packages and uses thereof
US8518697B2 (en) * 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
EP2155782A2 (en) * 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2185701A4 (en) 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
DK3178835T3 (da) * 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
US8956619B2 (en) * 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
BR112015011111A2 (pt) * 2012-11-30 2017-11-14 Roche Glycart Ag proteína multifuncional e formulação farmacêutica
CN111315768A (zh) * 2017-09-07 2020-06-19 库尔生物制药有限公司 具有缀合位点的t细胞调节性多聚体多肽及其使用方法
CN111886241A (zh) * 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法

Also Published As

Publication number Publication date
TWI795740B (zh) 2023-03-11
DK3157552T3 (da) 2020-01-13
CN106456733A (zh) 2017-02-22
JP6995151B2 (ja) 2022-02-21
TW201613966A (en) 2016-04-16
JP2020072733A (ja) 2020-05-14
AU2015277460B2 (en) 2020-10-08
AU2021204594A1 (en) 2021-07-29
CN106456733B (zh) 2021-03-16
AU2019203442A1 (en) 2019-06-06
EP3480213B1 (en) 2019-11-13
EP3480213A1 (en) 2019-05-08
CN113248624B (zh) 2025-02-07
JP2017519491A (ja) 2017-07-20
TW201946933A (zh) 2019-12-16
EP3483179B1 (en) 2020-09-16
HUE047255T2 (hu) 2020-04-28
US20180282392A1 (en) 2018-10-04
EP3157552B1 (en) 2019-10-23
PL3480213T3 (pl) 2020-05-18
WO2015195531A2 (en) 2015-12-23
EP3157552A4 (en) 2017-11-22
IL266570B (en) 2020-06-30
TWI722576B (zh) 2021-03-21
ES2770330T3 (es) 2020-07-01
PL3157552T3 (pl) 2020-05-18
KR20170030484A (ko) 2017-03-17
US20210238254A1 (en) 2021-08-05
WO2015195531A3 (en) 2016-02-25
EP3483179A1 (en) 2019-05-15
KR102252119B1 (ko) 2021-05-17
PT3157552T (pt) 2020-01-22
JP2020022491A (ja) 2020-02-13
IL275307A (en) 2020-07-30
AU2015277460A1 (en) 2016-11-24
CA2947489A1 (en) 2015-12-23
AU2021204594B2 (en) 2024-05-09
IL266570A (en) 2019-07-31
JP6652680B2 (ja) 2020-02-26
SG10202006338UA (en) 2020-08-28
HUE048076T2 (hu) 2020-07-28
ES2767259T3 (es) 2020-06-17
BR112016027897A2 (pt) 2017-10-24
DK3480213T3 (da) 2020-02-17
IL275307B (en) 2022-03-01
US20210047384A1 (en) 2021-02-18
JP6652932B2 (ja) 2020-02-26
TWI696633B (zh) 2020-06-21
CN113248624A (zh) 2021-08-13
US20200377569A1 (en) 2020-12-03
EP3157552A2 (en) 2017-04-26
IL248979A0 (en) 2017-01-31
TW202124435A (zh) 2021-07-01
AU2019203442B2 (en) 2021-04-08
CN113248623A (zh) 2021-08-13
PT3480213T (pt) 2020-02-04
JP7331075B2 (ja) 2023-08-22
US20170058015A1 (en) 2017-03-02
SG11201609876TA (en) 2017-01-27
JP2022046544A (ja) 2022-03-23

Similar Documents

Publication Publication Date Title
IL275307B (en) Syntac polypeptides and their uses
IL281273A (en) Adapted 21–FGF polypeptides and their uses
IL252216A0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
IL247014A0 (en) 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use
HUE044571T2 (hu) Módosított ciklopentapeptidek és alkalmazásaik
SG10201912019WA (en) Novel specific-binding polypeptides and uses thereof
IL250502B (en) New polypeptides
GB201405784D0 (en) Novel methods, polypeptides and uses thereof
GB201410031D0 (en) Polypeptides and uses thereof
IL254241A0 (en) Etv2 and its uses
IL251289B (en) New peptide derivatives and their use
SG11201610918RA (en) Peptides and uses thereof
GB201613143D0 (en) Polypeptides and uses thereof
GB201613142D0 (en) Polypeptides and uses thereof
GB201401973D0 (en) Antibody polypeptides and uses thereof
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie
GB201403024D0 (en) Polypeptides
GB201407419D0 (en) Conductive materials and uses thereof
GB201404728D0 (en) Disc-over incorporating disc-heads and disc-earning

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed